Holen Sie sich die Stockscreener-App
0.159
1.91%
-0.0031
Handel nachbörslich:
.16
0.001
+0.63%
Calidi Biotherapeutics Inc Aktie (CLDI) Neueste Nachrichten
CLDI Q4 2025 Earnings: Narrower-Than-Expected Loss Fails to Lift SharesAdjusted Earnings Analysis - The League of Women Voters of Texas
CLDI Q4 2025 Earnings: Narrower Loss Signals Progress in Clinical PipelineProfit Inflection Point - newsline.com
Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on June 9 - ACCESS Newswire
Calidi Biotherapeutics Announces Investor Webinar on June 9, 2026 - GlobeNewswire
Calidi Biotherapeutics (CLDI) Edges Lower, Testing Key Support at $0.16Regression Channel - newsline.com
CLDI Q4 2025 Earnings: Significant EPS Beat Highlights Progress in Oncolytic Virus Therapy DevelopmentFull Year Guidance - newsline.com
Calidi Biotherapeutics (CLDI) Hovers Near Key Support Amid Continued Selling PressureShakeout Pattern - newsline.com
Calidi Biotherapeutics, Inc. Files Form 8-K Disclosing Amended and Restated Warrant Agreement – Key Details and XBRL Data - Minichart
Calidi Biotherapeutics Amends Warrant in Private Placement - TipRanks
Calidi Biotherapeutics Amends Warrant for 17.4M Shares at $0.23; Stockholder OK Required - TradingView
Calidi (NYSE: CLDI) extends vesting and adjusts major warrant terms - Stock Titan
CLDI Q4 2025 Earnings: Narrower-Than-Expected Loss as Clinical Progress ContinuesROIC Trend Report - newsline.com
Number of shareholders of Calidi Biotherapeutics, Inc. – AMEX:CLDI - TradingView
Calidi Biotherapeutics Announces Online Abstract Acceptances at the 2026 ASCO Annual Meeting - Weekly Voice
Tumor-targeting virotherapy from Calidi to appear at 2026 ASCO - Stock Titan
Calidi Biotherapeutics (CLDI) Declines Slightly, Approaching Key Support at $0.16Put Flow Alert - newsline.com
Calidi Biotherapeutics Q4 2025 Earnings: Narrowed Loss Surprises, Stock DeclinesEarnings Season Review - newsline.com
Calidi Biotherapeutics Q4 2025 Earnings: Narrowed Loss Per Share Exceeds Expectations Despite Stock Decline - Newser
Calidi Biotherapeutics Provides Required NYSE American Disclosure - The Manila Times
Calidi Biotherapeutics discloses NYSE-required audit note on going concern status in 2025 financial report. - Pluang
Calidi Biotherapeutics, Inc. Issues Financial Statement Audit Report Highlighting Going Concern Assumption - Quiver Quantitative
Biotech Calidi’s 2025 audit report includes 'going concern' note - Stock Titan
Armistice Capital (CLDI) reports 1.11M shares, 9.99% ownership - Stock Titan
Calidi Highlights Q1 Results and RedTail Platform Progress - TipRanks
Calidi Biotherapeutics 1Q 2026: Net loss $4.42M, EPS $(0.43) — 10-Q Summary - TradingView
Calidi Biotherapeutics (CLDI) Q1 2026 loss, cash runway and warrant overhang detailed - Stock Titan
Calidi Biotherapeutics (NYSE: CLDI) Q1 2026 loss narrows as cash rises - Stock Titan
Biotech Calidi cuts costs, taps AI partner for CLD-401 IND - Stock Titan
Press Release: Calidi Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Operational Highlights - Moomoo
Calidi Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Operational Highlights - GlobeNewswire
Calidi Biotherapeutics Confirms Featured Speaker Presentation Tomorrow at the ASGCT Conference in Boston - GlobeNewswire
Calidi virotherapy delivers genetic meds inside tumors, ASGCT talk set - Stock Titan
TradingKey - TradingKey
How Calidi (CLDI) maintains its competitive edge | Q4 2025: Better Than ExpectedFree Cash Margin - Newser
Calidi Biotherapeutics, Inc. Files Form 8-K for Material Definitive Agreement and Common Stock Purchase Warrants – SEC Filing May 6, 2026 - Minichart
Calidi Biotherapeutics Issues Private Placement Warrant Financing - TipRanks
Calidi Biotherapeutics Issues Warrant for 17.4M Shares, Linked to Up to $4M Stock Buys at $0.23 - TradingView
Calidi Biotherapeutics (CLDI) grants 17.4M-share warrant linked to $4M equity - Stock Titan
Calidi Biotherapeutics announces underwritten public offering - Investing.com
CLDI Stock Price, Quote & Chart | CALIDI BIOTHERAPEUTICS INC (NYSEARCA:CLDI) - ChartMill
DEFA14A: Others - Moomoo
Calidi Biotherapeutics (CLDI) sets vote on reverse split and larger equity plan - Stock Titan
Calidi Biotherapeutics announces strategic partnership with Transferai - marketscreener.com
Calidi partners with TransferAI for CLD-401 regulatory filing By Investing.com - Investing.com South Africa
Calidi partners with TransferAI for CLD-401 regulatory filing - Investing.com
Calidi Biotherapeutics Announces Strategic Partnership With Transferai - TradingView
Calidi turns to AI software as it pushes CLD-401 toward filing - Stock Titan
Calidi (CLDI) Stock: What Is Driving the Price | Q4 2025: EPS Tops ViewsTax Rate Impact - newsline.com
Calidi (CLDI) Stock: Breakout Potential Analysis | Q4 2025: Better Than ExpectedVerified Stock Signals - Cổng thông tin điện tử tỉnh Lào Cai
CLDI (Calidi Biotherapeutics Inc.) posts 73.6% positive Q4 2025 EPS surprise, shares edge slightly lower in today’s trading.Revenue Diversification - Cổng thông tin điện tử tỉnh Lào Cai
Calidi Biotherapeutics Presents New Data on Its Lead Asset CLD-401 at the AACR Annual Meeting in April 2026 - marketscreener.com
Calidi says CLD-401 drove tumor immune response ahead of 2026 IND - Stock Titan
Calidi presents cancer therapy data at AACR meeting By Investing.com - Investing.com India
Certain Stock Options of Calidi Biotherapeutics, Inc. are subject to a Lock-Up Agreement Ending on 21-APR-2026. - marketscreener.com
1.27%
1.43%
Kapitalisierung:
|
Volumen (24h):